1. A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01). Issue 12 (24th April 2020) Authors: Balana, Carmen; Vaz, Maria Angeles; Manuel Sepúlveda, Juan; Mesia, Carlos; del Barco, Sonia; Pineda, Estela; Muñoz-Langa, Jose; Estival, Anna; de las Peñas, Ramón; Fuster, Jose; Gironés, Regina; Navarro, Luis Miguel; Gil-Gil, Miguel; Alonso, Miriam; Herrero, Ana; Peralta, Sergio; Olier, Clara; Pe... Journal: Neuro-oncology Issue: Volume 22:Issue 12(2020) Page Start: 1851 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma: a phase Ib/II, open-label, multicentre, randomised study. Issue 4 (13th July 2020) Authors: Rosenthal, Mark; Clement, Paul M; Campone, Mario; Gil-Gil, Miguel J; DeGroot, John; Chinot, Olivier; Idbaih, Ahmed; Gan, Hui; Raizer, Jeffrey; Wen, Patrick Yung; Pineda, Estela; Donnet, Valerie; Mills, David; El-Hashimy, Mona; Mason, Warren Journal: ESMO open Issue: Volume 5:Issue 4(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Clinical implications of the intrinsic molecular subtypes of breast cancer. (1st November 2015) Authors: Prat, Aleix; Pineda, Estela; Adamo, Barbara; Galván, Patricia; Fernández, Aranzazu; Gaba, Lydia; Díez, Marc; Viladot, Margarita; Arance, Ana; Muñoz, Montserrat Journal: Breast Issue: Volume 24(2015)Supplement 2 Page Start: S26 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trial. Issue 6 (May 2017) Authors: Pineda, Estela; Salud, A; Vila-Navarro, E; Safont, MJ; Llorente, Beatriz; Aparicio, J; Vera, R; Escudero, P; Casado, E; Bosch, C; Bohn, U; Pérez-Carrión, R; Carmona, A; Ayuso, JR; Ripollés, T; Bouzas, R; Gironella, M; García-Albéniz, X; Feliu, J; Maurel, J Journal: Tumor biology Issue: Volume 39:Issue 6(2017) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Is There a Role For PET/CT With Esophagogastric Junction Adenocarcinoma?. (March 2015) Authors: Fuster, David; Mayoral, Maria; Rubello, Domenico; Pineda, Estela; Fernández-Esparrach, Gloria; Pagès, Mario; Colletti, Patrick M.; Pons, Francesca Journal: Clinical nuclear medicine Issue: Volume 40:Number 3(2015) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Is There a Role For PET/CT With Esophagogastric Junction Adenocarcinoma?. (March 2015) Authors: Fuster, David; Mayoral, Maria; Rubello, Domenico; Pineda, Estela; Fernández-Esparrach, Gloria; Pagès, Mario; Colletti, Patrick M.; Pons, Francesca Journal: Clinical nuclear medicine Issue: Volume 40:Number 3(2015) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. LoVo colon cancer cells resistant to oxaliplatin overexpress c‐MET and VEGFR‐1 and respond to VEGF with dephosphorylation of c‐MET. Issue 5 (3rd February 2015) Authors: Mezquita, Belén; Pineda, Estela; Mezquita, Jovita; Mezquita, Pau; Pau, Montserrat; Codony‐Servat, Jordi; Martínez‐Balibrea, Eva; Mora, Conchi; Maurel, Joan; Mezquita, Cristóbal Journal: Molecular carcinogenesis Issue: Volume 55:Issue 5(2016:May) Page Start: 411 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. MET inhibitors in cancer: pitfalls and challenges. (2nd January 2020) Authors: Oliveres, Helena; Pineda, Estela; Maurel, Joan Journal: Expert opinion on investigational drugs Issue: Volume 29:Number 1(2020) Page Start: 73 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Nuclear factor‐kappa B and interleukin‐6 related docetaxel resistance in castration‐resistant prostate cancer1. Issue 5 (4th October 2012) Authors: Codony‐Servat, Jordi; Marín‐Aguilera, Mercedes; Visa, Laura; García‐Albéniz, Xabier; Pineda, Estela; Fernández, Pedro L.; Filella, Xavier; Gascón, Pere; Mellado, Begoña Journal: Prostate Issue: Volume 73:Issue 5(2013) Page Start: 512 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Pseudoprogression as an adverse event of glioblastoma therapy. (3rd November 2017) Authors: Balaña, Carmen; Capellades, Jaume; Pineda, Estela; Estival, Anna; Puig, Josep; Domenech, Sira; Verger, Eugenia; Pujol, Teresa; Martinez‐García, Maria; Oleaga, Laura; Velarde, JoseMaria; Mesia, Carlos; Fuentes, Rafael; Marruecos, Jordi; Del Barco, Sonia; Villà, Salvador; Carrato, Cristina; Gallego... Journal: Cancer medicine Issue: Volume 6:Number 12(2018:Dec.) Page Start: 2858 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗